Document Detail


Treatment of disability in peripheral arterial disease: new drugs.
MedLine Citation:
PMID:  15379614     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Peripheral arterial disease is a major manifestation of systemic atherothrombosis that affects a large segment of the adult population. The major treatment goals for this population are to address the marked increase risk in cardiovascular events and then secondarily to treat the disability and reduced exercise tolerance. The primary goals for treating the limb symptoms of PAD are to improve functional capacity, exercise performance and qualify of life. Exercise training in a formal setting, revascularization with angioplasty and cilostazol all have proven efficacy. In addition, there is a major interest in developing new pharmacologic therapies for claudication. Prostaglandins have been utilized for critical leg ischemia for decades, but recent trials have not demonstrated any role for these drugs in treating claudication. Carnitine and its derivatives (propionyl-L-carnitine) have been shown to improve treadmill exercise performance and quality of life. These drugs also have an excellent safety profile. A final promising class of drugs is statins that not only reduce the increased risk of ischemic events but also appear to improve claudication symptoms.
Authors:
William R Hiatt
Related Documents :
8000114 - Medical management of peripheral arterial disease.
14562764 - Postocclusive reactive hyperemia in healthy volunteers and patients with peripheral vas...
12469984 - Management of patients with intermittent claudication.
663544 - Effects of physical training in intermittent claudication.
22454894 - The assessment of β-adrenoceptor blocking drugs in hyperthyroidism.
7674404 - Pulmonary function and posture in traumatic quadriplegia.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current drug targets. Cardiovascular & haematological disorders     Volume:  4     ISSN:  1568-0061     ISO Abbreviation:  Curr Drug Targets Cardiovasc Haematol Disord     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-09-21     Completed Date:  2005-03-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101123341     Medline TA:  Curr Drug Targets Cardiovasc Haematol Disord     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  227-31     Citation Subset:  IM    
Affiliation:
Divisions of Geriatrics and Cardiology, Section of Vascular Medicine, University of Colorado Health Sciences Center and The Colorado Prevention Center, Denver, Colorado, USA. will.hiatt@uchsc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / therapeutic use
Arteriosclerosis / complications
Carnitine / therapeutic use
Clinical Trials as Topic
Exercise Therapy
Humans
Intermittent Claudication / etiology,  therapy
Ischemia / drug therapy,  etiology
Leg / blood supply
Peripheral Vascular Diseases / drug therapy*,  etiology
Prostaglandins / therapeutic use
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Prostaglandins; 541-15-1/Carnitine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Critical limb ischemia: definition and natural history.
Next Document:  Exercise rehabilitation for the patient with intermittent claudication: a highly effective yet under...